Economic Evaluation of Tobacco Treatments From the Screen ASSIST Lung Cancer Screening Trial

JAMA Netw Open. 2026 Jan 2;9(1):e2555332. doi: 10.1001/jamanetworkopen.2025.55332.

Abstract

Importance: Integrating smoking cessation interventions within lung cancer screening (LCS) programs may significantly reduce smoking-related morbidity and mortality. Data on costs and cost-effectiveness of smoking cessation interventions in the context of LCS can foster the dissemination of effective treatments.

Objective: To evaluate the cost-effectiveness from a health system perspective of 8 smoking cessation treatment strategies evaluated in the context of the Screen Aiding Screening Support In Stopping Tobacco (ASSIST) trial among patients undergoing LCS in 1 large health care system.

Design, setting, and participants: The Screen ASSIST trial used a 3-way factorial design testing the effectiveness of 8 combinations of smoking cessation treatments at a health system in Massachusetts with 11 participating LCS sites. In this economic evaluation, costs and cost-effectiveness were evaluated prospectively and contextualized through sensitivity analyses. Participants included English-speaking and Spanish-speaking patients who smoked and were scheduled for LCS between April 2019 and July 2023.

Interventions: Participants were randomized to 4 vs 8 counseling sessions, 2 vs 8 weeks of nicotine replacement therapy (NRT), and screening for social determinants of health (SDH) vs no screening.

Main outcomes and measures: The primary effectiveness outcome was self-reported 7-day smoking abstinence at 6 months. Cost measures included both start-up and operating costs, with incremental cost per quit (ICQ) calculated relative to usual care.

Results: Screen ASSIST had 642 participants (mean [SD] age, 64.0 [6.5] years; 358 female [55.8%]; mean [SD] 36.8 [19.4] pack-years; mean [SD] 16.2 [8.2] cigarettes per day). Start-up costs for the program were $131 371, primarily for electronic health record programming ($124 903). Operating costs for the intervention conditions ranged from $196 272 to $274 865 for 642 participants. The ICQ of 8 counseling sessions, 2 weeks NRT, and no SDH screening was $3050 (95% CI, $1286-4815), the most cost-effective condition. Per-patient costs and ICQ would be lower in health systems serving larger patient populations.

Conclusions and relevance: In this economic evaluation of smoking cessation treatment in LCS, 8-session counseling combined with 2 weeks of NRT was a cost-effective strategy, with a favorable ICQ relative to usual care and other treatment strategies evaluated. These findings are relevant for health systems considering integrating smoking cessation programs with LCS services.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Cost-Benefit Analysis
  • Counseling / economics
  • Early Detection of Cancer* / economics
  • Early Detection of Cancer* / methods
  • Female
  • Humans
  • Lung Neoplasms* / diagnosis
  • Lung Neoplasms* / economics
  • Male
  • Massachusetts
  • Middle Aged
  • Smoking Cessation* / economics
  • Smoking Cessation* / methods
  • Tobacco Use Cessation Devices* / economics